Videos

At AAIC 2025, the founder and CEO at Veravas discussed the company’s VeraBIND tau pathology blood test, highlighting its potential to detect Alzheimer disease earlier with high accuracy. [WATCH TIME: 4 minutes]

At AAIC 2025, the chief executive officer at ALZpath discussed the growing adoption of the company’s pTau217 antibody blood test for AD research, emphasizing its potential role in early detection. [WATCH TIME: 4 minutes]

The principal scientist of neuroscience discovery at Merck presented preclinical data at AAIC 2025 supporting the development of MK-2214, an anti-tau antibody designed to slow or prevent the progression of AD. [WATCH TIME: 5 minutes]

Panelists discuss how they select between wake-promoting medications (modafinil, armodafinil, and solriamfetol) by explaining neurotransmitter mechanisms to patients while acknowledging that practical factors like insurance coverage and accessibility often drive treatment decisions more than theoretical mechanisms.

Panelists discuss how they approach measuring sleepiness in patients with OSA, with emphasis on trusting patient reports over relying solely on objective tests like the Epworth Sleepiness Scale, which they view as a useful screening tool but inadequate by itself due to patients often minimizing their symptoms.

Neurology News Network. for the week ending August 16, 2025. [WATCH TIME: 4 minutes]

The medical director of CNS Clinical Development at AskBio discussed long-term data presented at ATMRD from the company’s phase 1b assessing the investigational gene therapy AB-1005 in Parkinson disease. [WATCH TIME: 6 minutes]

Ali Habib, MD, and Arjun Seth, MD, discuss how B-cell–targeted therapies represent a promising upstream treatment approach for myasthenia gravis that could provide more sustained efficacy compared with current downstream treatments like complement inhibitors and FcRn antagonists, with CD19-targeting agents like inebilizumab showing particular promise in clinical trials for both acetylcholine receptor and MuSK antibody subtypes.

The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonwealth University discussed the next steps in advancing GLP-1s for idiopathic intracranial hypertension and the research necessary to further understand their therapeutic impact. [WATCH TIME: 3 minutes]

At CMSC 2025, assistant professor of neurology at the University of California, San Francisco discussed progress on the integration of biomarkers into clinical practice for multiple sclerosis. [WATCH TIME: 4 minutes]

Panelists discuss how the treatment paradigm for Dravet syndrome has dramatically shifted with newer FDA-approved medications (cannabidiol, stiripentol, and fenfluramine) now recommended as first- and second-line therapies alongside traditional options such as valproate and clobazam, emphasizing that these novel mechanisms offer distinct advantages and should be used early rather than as last-resort treatments, with risk evaluation and mitigation strategies (REMS) programs and specialty pharmacies actually improving patient access and monitoring.

The clinical assistant professor in movement disorders at Jefferson Health outlined a patient-centered, lifestyle-first approach to managing Parkinson nonmotor symptoms. [WATCH TIME: 4 minutes]

Panelists discuss how patients with Dravet syndrome face elevated sudden unexplained death in epilepsy (SUDEP) risk compared with other epilepsy populations, emphasizing the importance of early family education about risk factors such as convulsive seizures and medication adherence, while highlighting that newer therapies show promise in reducing both seizure frequency and SUDEP risk through better seizure control and decreased status epilepticus occurrence.

The associate professor of neurology at Johns Hopkins Medicine previewed a 2025 AUPN panel exploring AI’s clinical, research, and educational applications, along with the ethical considerations shaping its responsible adoption. [WATCH TIME: 2 minutes]

The chief medical officer at Acumen Pharmaceuticals discussed the benefits of using the blood-based p-tau 217 biomarker to improve screening accuracy and reduce patient burden in AD. [WATCH TIME: 5 minutes]

The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonwealth University detailed published findings on GLP-1 receptor agonists significantly improving outcomes and lowering mortality in idiopathic intracranial hypertension, regardless of BMI. [WATCH TIME: 5 minutes]

Panelists discuss how FDA-approved medications like modafinil, armodafinil, and solriamfetol serve both therapeutic and diagnostic purposes in treating residual sleepiness, with responses varying across different sleep disorder populations but consistently helping patients recognize their true level of impairment.

Panelists discuss how approximately 20% to 30% of patients compliant with CPAP therapy still experience pathological sleepiness, requiring clinicians to plant early expectations about potential need for additional pharmacological treatment and address patient disappointment when CPAP alone isn't sufficient.

In the third episode, Salloway emphasizes the need for careful patient selection when prescribing donanemab to minimize serious risks, highlighting the value of the newly approved safer dosing regimen. Supported by Eli Lilly.

Dementia expert Stephen Salloway, MD, PhD, overviews the stepwise donanemab regimen approved by the FDA, citing how it not only reduces ARIA rates but preserves the same level of amyloid reduction as the original dosing. Supported by Eli Lilly.

Neurology News Network. for the week ending August 9, 2025. [WATCH TIME: 4 minutes]

Expert Stephen Salloway, MD, discussed findings from the TRAILBLAZER-ALZ 6 study, highlighting how a stepwise donanemab dosing regimen significantly lowered rates of ARIA in early Alzheimer disease. Supported by Eli Lilly.

The director of pediatric epilepsy at NYU Langone Medical Center shared expert insights on improving transitions from pediatric to adult epilepsy care. [WATCH TIME: 3 minutes]

The corporate vice president of medical information and research at Theranica discussed long-term findings presented at AHS 2025 covering the company’s Nerivio remote electrical neuromodulation device for patients with migraine. [WATCH TIME: 5 minutes]

Two experts from Cerevance discussed data from the company’s posters recently presented at AAIC 2025, which highlighted potential therapeutic targets for Alzheimer disease. [WATCH TIME: 5 minutes]

Panelists discuss how SCN1A genetic testing has enabled earlier diagnosis of Dravet syndrome, though some clinicians still hesitate to order tests due to discomfort with genetics, emphasizing that early genetic confirmation is crucial for avoiding contraindicated sodium channel medications, implementing appropriate treatments, and providing families with answers and community connections that improve long-term outcomes.

Panelists discuss how early recognition of Dravet syndrome's key clinical features—including prolonged seizures triggered by fever or illness in the first year of life, the importance of genetic testing for SCN1A variants, and the progressive nature of the condition that evolves from initial febrile seizures to multiple seizure types alongside developmental delays—can support timely diagnosis and improve long-term outcomes for pediatric patients.

At AAIC 2025, the head of AD, MS and Immunology Development Units at Biogen discussed ongoing research efforts targeting tau pathology in AD, specifically the company's investigational candidate BIIB080. [WATCH TIME: 6 minutes]

The neurologist at Duke Health provided insights on how chronic demyelinating inflammatory polyneuropathy treatment is evolving toward biomarker-driven, personalized approaches at the 2025 Carolina Neuromuscular Summit. [WATCH TIME: 2 minutes]

The director of the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital gives clinicians insight on the reasons to attend the 2025 Carolina Neuromuscular Summit. [WATCH TIME: 3 minutes]